Skip to main content

Coronavirus: Vaccination

Question for Department of Health and Social Care

UIN HL2581, tabled on 9 September 2021

To ask Her Majesty's Government what assessment they have made of the occurrence of patients suffering from Guillain-Barré syndrome following their COVID-19 vaccination; and which vaccines were involved in each case.

Answered on

23 September 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has been closely monitoring and assessing all reports of Guillain-Barre syndrome (GBS) during the COVID-19 vaccination program. GBS has occurred very rarely in individuals following vaccination in the United Kingdom. Whilst it was not possible to establish a causal association between any of the vaccines and GBS based on the available data, there was sufficient evidence to warrant a precautionary statement about these very rare reports in the AstraZeneca vaccine Product Information (PI) in order to alert patients and healthcare professionals of the signs and symptoms so that adequate supportive care and treatment can be sought and provided. This was included in the PI for the AstraZeneca vaccine in August 2021.